IL-STATS
25.7.2017 09:32:10 CEST | Business Wire | Press release
STATS, the global leader in sports data and intelligence, has launched an innovative new product, STATS Edge. STATS Edge is a search and analytics application powered by artificial intelligence that enables football teams to instantly find video clips and analyse complex patterns in a game with more speed and accuracy than ever before. With the power of AI-driven analytics at their fingertips, analysts can instantly and effectively assess in detail a team’s strengths and weaknesses while focusing on various aspects of the game.
Drawing on STATS’ rich history in data collection and analysis, STATS Edge will utilise data from the Premier League, Championship, La Liga, Ligue de Football Professionnel, Serie A, Bundesliga, Qatar Stars League, Champions League and more. STATS Edge will initially be available in five languages.
STATS Edge unifies football data and video through an easy-to-use and intuitive user interface, developed in close partnership with top English, French and Spanish clubs through a design-thinking methodology. This allows everyone in the football club – from match analysts to the manager – to analyse, annotate and share insights on the same platform.
“It’s increasingly difficult for clubs to process and analyse all the relevant data points available and distil complex information into timely, accurate insight,” said Kenneth Fuchs, STATS’ CEO. “On top of that, traditional analytics don’t always speak the visual language of players and coaches. We’ve applied computer vision and artificial intelligence to bring new levels of context and efficiency to teams already using video for their match preparations. It’ll save them time, allow them to develop proprietary results, and help get them the information to make, share and track the best decisions.”
The STATS Edge search engine allows managers and analysts to use their football vocabulary within a search box to find relevant video clips in seconds across entire leagues or competitions, regardless of the complexity of their queries. They can link a multitude of events and playing styles to search, which allows the execution of more than 1,000 search combinations.
The ability to search across players, teams, styles, set plays and more using natural language is a substantial step forward in accessing complex tracking data in a simple interface. For example, STATS Edge lets users quickly find and retrieve all of a team’s counter attacks which led to goals, a player’s key events such as shots or crosses in the last five games, or passes into a custom defined zone on the pitch. This use of analytics also helps clubs assess the value of a transfer target in order to reach a fully informed decision before making an investment.
Once clips are identified, STATS’ proprietary Exemplar Search, built by its award-winning data science team, can instantly find clips of similar plays at the click of a button. By using AI algorithms, the platform reads the combination of player and ball trajectories as well as events in any clip to retrieve the respective Exemplar Search results.
STATS Edge further builds on the power of AI to provide exciting and intuitive analytical features, starting with set plays and transitions. By dynamically specifying a zone on the field and other variables, the manager and analyst instantly accesses in-depth analysis and all corresponding videos. For example, in set-play analysis of an opponent, one can identify target zones and link them to the most dangerous players and their shooting or goal efficiency. In transition analysis, one can analyse the key players involved, as well as their most typical behaviour after winning or losing the ball.
About STATS
STATS is the global leader in sports intelligence. Trusted by the world’s most innovative teams, leagues and brands seeking the winning edge at the intersection of sports and technology, STATS combines the industry’s fastest and most accurate data platform with video analysis, sports content and research, player tracking through STATS SportVU®, and a range of customisable digital solutions for brands. The pioneer of live sports data, STATS continues to speed innovation in the industry today to enhance both team performance and fan experience. For more information, go to www.stats.com and follow STATS on Twitter @STATSInsightsUK .
View source version on businesswire.com: http://www.businesswire.com/news/home/20170725005426/en/
Contact:
STATS
Dennis Dougherty, 847-583-2680
ddougherty@stats.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom